C. Richard-Pebrel

Centre Hospitalier Universitaire de Clermont-Ferrand

Papers

1

Total Citations

16

H-Index

1

About

Dr. C. Richard-Pebrel is a hematologist-oncologist whose research focuses on the molecular complexities of myeloproliferative neoplasms (MPNs) and chronic myeloid leukemia (CML). Their most cited work, a 2009 study with 16 citations, made a seminal contribution by demonstrating that a thrombocytosis emerging in Philadelphia-positive CML patients achieving molecular response to imatinib can unmask a concurrent JAK2V617F-positive MPN. This finding challenged the conventional view of single-disease pathogenesis and highlighted the phenomenon of dual clonal hematopoiesis, offering critical insights for clinical management. Dr. Richard-Pebrel’s work underscores the importance of vigilant monitoring in targeted therapy, revealing how treatment can unmask latent disease. Their research has shaped understanding of clonal evolution and therapeutic resistance, providing a framework for diagnosing and managing overlapping MPN syndromes. With a career dedicated to unraveling the genetic interplay in hematologic malignancies, Dr. Richard-Pebrel continues to influence both diagnostic practice and the study of clonal heterogeneity in blood cancers.

Research Focus

Key Achievements

1
H-Index
1
Papers
16
Total Citations
16
Avg Citations/Paper
🏆 Most Cited Paper
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm
16 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Centre Hospitalier Universitaire de Clermont-Ferrand

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago